Latest News for Uneeqo Stock (OTC:UNEQ)

Uneeqo Inc is a technology company engaged in providing applications and software solutions covering several business areas like Telecom, Finance, Mobile Application, Medical, and Travel applications.

News

Intraday Update

Markets

Movers

Trading Ideas

AGEEF

AKTAF

BCOV

BNNLF

BSAC

BTTR

CASI

CCOZF

CEIX

CGAAY

CGCO

CGRA

CJPRY

CLSH

CTRM

CWBHF

CYBQF

DLUEY

DNTUY

ECOL

EJPRY

ERMAY

EUOT

FEIM

GDNEF

GFGSF

GGLT

GNMK

GPHBF

GSUM

GWRRF

HBCYF

HBRM

HZNFF

ITCB

JAPAY

JAPSY

JGFCF

KMTUY

KPCPY

LFAP

LIVE

LNTH

LRSNF

MALJF

MBGRF

MFMLF

MOBQ

MSPC

MZDAY

NDBKY

NGVC

NINOY

NODK

OSUR

PDPYF

PLPRF

PETROTEQ ENERGY INC by Petroteq Energy Inc.

PQEFF

QEGY

RCON

RDS-B

RMTD

RSSV

RWLK

RYKKY

SCIE

SHMDF

SRDX

STAY

TARO

TBLMY

TOPS

TOSYY

TRNX

TVTY

UBQU

UBSI

UNEQ

USGDF

Stocks That Hit 52-Week Lows On Thursday

Movers & Shakers

General

AAMAF

AAWW

ABMD

ACGBF

ACGBY

ACOR

ACRS

ADAP

ADXS

AERI

AGFS

AHKSY

ALFVY

ALNA

AMGDF

AMVMF

ANDE

APEN

ARCH

ARGGY

ARZTY

ASCK

ASGLY

ATRA

AVAV

AWRE

BACHY

BAFYY

BASFY

BBBY

BCDA

BEAT

BELFB

BFIN

BLCM

BLIN

BLMN

BMRN

BMYMP

BNDSY

BNFT

BNKXF

BRSWQ

BrightSphere Investment Group plc Ordinary Shares

BSIG

CARS

CBKC

CBPX

CDEV

CDTI

CDTX

CELZ

CENT

CENTA

CESDF

CICHY

CICOY

CINR

CISN

CKHUY

CLSK

CLVS

CLXT

CMCM

CMVLF

COMM

CORV

CSBR

CTRA

CVLT

CWAFF

CYCN

Changyou Limited American Depositary Share

CYOU

DDAIF

DGMLF

DMLRY

DNJR

DOYU

Stocks That Set New 52-Week Lows Friday Morning

Uneeqo Inc

Oppenheimer analyst Bryan Blair maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Outperform and raises the price target from $133 to $142.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Xylem, Raises Price Target to $142

New partnership will be foundational to Panasas' global growth and expansion
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.panasas.com%2F&amp;esheet=53937763&amp;newsitemid=20240418133456&amp;lan=en-US&amp;anchor=Panasas&amp;index=1&amp;md5=f288530ea8257ccc2937f8635e8da8f9">Panasas</a>, a leading data solutions provider for high-performance computing (HPC) and artificial intelligence (AI), and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avnet.com%2Fwps%2Fportal%2Fus%2F&amp;esheet=53937763&amp;newsitemid=20240418133456&amp;lan=en-US&amp;anchor=Avnet&amp;index=2&amp;md5=c47f0b01058fda5036772b134ba907d0">Avnet</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVT#NASDAQ">AVT</a>) today announced an agreement enabling Panasas to use Avnet Integrated, the global advanced systems integration arm of Avnet, as its primary manufacturing and fulfillment operations partner. The partnership will enable Panasas to benefit from Avnet's global supply chain and worldwide manufacturing footprint, strengthening Panasas' competitive position and ability to support its growth across the global HPC and AI storage market.
"Avnet Integrated excels in optimizing IT product development, manufacturing at scale, and solutions deployment, globally. This enables our customers to increase their pace of innovation and ultimately elevate their competitiveness," said Nicole Enright, President of Avnet Integrated. "The agreement with Panasas provides access to our global manufacturing and supply chain capabilities, accelerating both time to market and time to scale, for their solutions.
"One of my first goals when joining Panasas was to move to a best-in-class operational model that would enable greater supply chain efficiency and flexibility in order to meet the demand growth that we are seeing across our global customer base, while also accelerating our ability to bring a broader range of solutions to market. This agreement with Avnet Integrated is an important part of that journey," said Ken Claffey, CEO at Panasas. "Our collaboration will enhance our ability to deliver compelling technical value with strong ROI to customers globally, thanks to Avnet's comprehensive integration and worldwide supply chain proficiencies.
Avnet Integrated will be the principal commercial manufacturing partner for Panasas worldwide. It will employ Avnet's intelligent solutions for efficient supply chain management, integration, and international logistics.
To learn more about Panasas, please visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.panasas.com&amp;esheet=53937763&amp;newsitemid=20240418133456&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.panasas.com&amp;index=4&amp;md5=4d5c520fdb2721aa0bc5dc0ce2d6cc12">https://www.panasas.com</a>.

Panasas Signs Worldwide Manufacturing And Fulfillment Partnership With Avnet

<ul>
<li>GM Energy's initial product offerings for home customers are now available for purchase through a newly launched e-commerce platform</li>
<li>Flexible GM Energy bundle offerings and software integration through GM vehicle brand apps provide customers with greater control over personal energy management between vehicle, home and other products</li>
<li>Energy Live platform provides educational resource to learn more about benefits of personal energy management, grid resiliency and an all-electric lifestyle</li>
</ul>

GM Energy Releases New Product Suite, Offering Customers Ability To Transfer Power Between EVs And Homes

Oncternal Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fourth dosing cohort will receive ONCT-534, the company's dual-action androgen receptor inhibitor (DAARI), at a dose of 300 mg taken orally each day. The decision to proceed to this higher dose level was made by the study's Safety Review Committee (SRC) after reviewing data from the patients treated to date, including the third dose level of 160 mg ONCT-534 daily. &nbsp;
"Reaching the 300 mg dose level represents a significant milestone for our ONCT-534 program. The drug has been well tolerated so far, and based on preclinical analyses, we are optimistic that study participants are receiving doses of ONCT-534 that may be within the active dose range for antitumor activity," said Salim Yazji M.D., Chief Medical Officer at Oncternal Therapeutics. "We continue to see strong demand from investigators and patients to participate in the study and expect to continue enrolling at a brisk pace. We look forward to announcing initial efficacy and safety data from the study, which we expect will be at the end of this quarter."
About Study ONCT-534-101 Study ONCT-534-101 is a Phase 1/2, single-arm, open-label, multi-center study to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of ONCT-534 in patients with mCRPC who have relapsed or are refractory to approved ARPIs including enzalutamide, abiraterone, apalutamide, and darolutamide. After the safety and tolerability and preliminary antitumor activity of ONCT-534 have been assessed in Phase 1, Phase 2 will commence to further evaluate the safety and preliminary antitumor activity of ONCT-534 to support selecting an optimal dose.

Biotech

ONCT

Oncternal Announces First Patient Dosed In Fourth Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer

LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1.73) by 32.95 percent. This is a 77.69 percent increase over losses of $(5.20) per share from the same period last year. The company reported quarterly sales of $2.43 million which beat the analyst consensus estimate of $2.28 million by 6.40 percent. This is a 12.99 percent increase over sales of $2.15 million the same period last year.

Earnings

LGMK

LogicMark Q4 Adj EPS $(1.16) Beats $(1.73) Estimate, Sales $2.43M Beat $2.28M Estimate

Oppenheimer analyst Chris Kotowski maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Outperform and lowers the price target from $55 to $54.

Oppenheimer Maintains Outperform on U.S. Bancorp, Lowers Price Target to $54

U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Thursday.
Shares of Equifax Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/efx#NYSE">EFX</a>) fell sharply in today&rsquo;s pre-market trading after the company reported worse-than-expected first-quarter sales results and issued adjusted <a href="https://www.benzinga.com/quote/EFX/earnings">guidance below estimates</a>.
Equifax posted quarterly sales of $1.389 billion, missing market estimates of $1.400 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Equifax shares dipped 9.5% to $215.00 in pre-market trading. 
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Funko, Inc.(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fnko#NASDAQ">FNKO</a>) shares fell 12.2% to $5.02 in pre-market trading after gaining around 5% on Wednesday.</li>
<li>Rani Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rani#NASDAQ">RANI</a>) shares fell 8.4% to $7.18 in pre-market trading after gaining 14% on Wednesday.</li>
<li>Tevogen Bio Holdings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tvgn#NASDAQ">TVGN</a>) shares fell 7.2% to $2.12 in pre-market trading after declining 3% on Wednesday.</li>
<li>Synovus Financial Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snv#NYSE">SNV</a>) shares declined 6.8% to $34.10 in pre-market trading as the company posted weaker-than-expected results for its first quarter.</li>
<li>Bank of Hawaii Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/boh#NYSE">BOH</a>) declined 5.7% to $53.00 in pre-market trading.</li>
<li>Etsy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etsy#NASDAQ">ETSY</a>) fell 4.3% to $64.60 in pre-market trading. Morgan Stanley analyst Lauren Schenk downgraded Etsy from Equal-Weight to Underweight and lowered the price target from $64 to $55.</li>
<li>Snap-on Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sna#NYSE">SNA</a>) shares fell 3.9% to $272.53 in pre-market trading following weak quarterly sales.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38311966/izea-worldwide-and-2-other-stocks-under-3-insiders-are-buying"> IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Penny Stocks

Small Cap

Pre-Market Outlook

ETSY

FNKO

RANI

TVGN

Equifax Reports Weak Sales, Joins Synovus Financial And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

DCFCW

Trading Halt: Halted at 9:02:22 a.m. ET - Trading Halt: Halt News Pending

DCFC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Uneeqo Stock (OTC:UNEQ)

Thursday, February 20, 2020

Friday, August 02, 2019